RxDoctor Payments Data

Anna Fuder Boehm, APRN

Psychiatric/Mental Health · Mesa, AZNPI 1619476389

Payments from drug & device makers

$1,407in general payments, 2019–2025

Across 35 payments — averaging $40.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$461
  • Johnson & Johnson$359
  • Teva Pharmaceuticals USA, Inc.$147
  • Otsuka America Pharmaceutical, Inc.$133
  • AbbVie$133
  • Vanda Pharmaceuticals Inc.$110
  • plus $64 from 1 others

What the payments were for

  • Food & beverage$1,36197%
  • Education$453%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,407 in reported general payments places this provider in the 75th percentile of 1,230 psychiatric/mental health providers in Arizona.

See all psychiatric/mental health providers in Arizona

Medicare billing

Part B allowed, 2024
$8,152
Medicare patients
23
Services billed
79

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate18$144,745
Invega SustennaPaliperidone Palmitate38$136,668
AustedoDeutetrabenazine22$101,109
Abilify MaintenaAripiprazole17$40,979
VraylarCariprazine Hcl16$23,089
Aripiprazole59$3,920
Duloxetine Hcl125$3,034
Olanzapine77$2,723
Divalproex Sodium ErDivalproex Sodium66$2,622
Quetiapine Fumarate125$2,489
Lurasidone Hcl16$2,455
Trazodone Hcl157$2,173
Clozapine42$2,118
Hydroxyzine Hcl79$1,730
Haloperidol35$1,413

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$64$144,74518 claims
Johnson & JohnsonInvega Sustenna$359$136,66838 claims
Teva Pharmaceuticals USA, Inc.Austedo, Loxapine$147$101,85837 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$133$40,97917 claims
AbbVieVraylar$133$23,08916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,230 psychiatric/mental health providers in Arizona.

Other psychiatric/mental health in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →